CD274 and non-small cell lung carcinoma: The PD-L1 expression on tumor cells was initially identified as logical biomarker for the prediction of treatment response to anti-PD-1/anti-PD-L1 therapies, and this topic has been largely investigated across different tumor types (especially melanoma and NSCLC) with conflicting results [11].